Læknablaðið - 15.06.2008, Blaðsíða 34

FRÆÐIGREINAR
YFIRLITSGREIN
fordómar í garð þessa heilkennis. Brýnt er að
eyða þessum fordómum og byggja upp stefnu í
greiningu og meðferð. Til gamans má benda á að
margir viðurkenndir sjúkdómar, sem dæmi má
nefna vöðvaspennuheilkenni (dystonia), vanstarf-
semi í skjaldkirtli (hypothyroidism) og vangahvot
(trigeminal neuralgia), voru áður fyrr taldir vera
af sálrænum toga.
Mikilvægt er að greina vefjagigtarheilkennið á
fyrstu stigum því að snemmtæk íhlutun er væn-
leg til bata. Til að svo megi verða er mikilvægt að
læknar, sjúkraþjálfarar, skólahjúkrunarfræðingar
og annað heilbrigðisstarfsfólk sé meðvitað um
einkenni vefjagigtar. Meðferð sem tekur á sem
flestum einkennum heilkennisins og þar sem fjöl-
skyldan er þátttakandi í meðferðinni hefur gefið
góðan árangur.
Þakkir
Arnór Víkingsson gigtarlæknir fær þakkir fyrir
ómælda aðstoð við greinarskrifin, yfirlestur grein-
arinnar og ábendingar. Auðna Ágústsdóttir doktor
í hjúkrunarfræði fær einnig sérstakar þakkir fyrir
yfirlestur greinarinnar og góðar ábendingar.
Heimildir
1. Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL.
Primary fibromyalgia (fibrositis): clinical study of 50 patients
with matched normal controls. Semin Arthritis Rheum. 1981;
11:151-71.
2. Yunus MB, Masi AT. Juvenile primary fibromyalgia
syndrome. A clinical study of thirty-three patients and
matched normal controls. Arthritis Rheum 1985; 28:138-45.
3. Romano TJ. Fibromyalgia in children; diagnosis and
treatment. W V Med J 1991; 87:112-4.
4. Yunus MB, Masi AT, Calabro JJ, Shah IK. Primary
fibromyalgia. Am Fam Physician 1982; 25:115-21.
5. Carmona L, Ballina J, Gabriel R, Laffon A; EPISE Study
Group. The burden of musculoskeletal diseases in the
general population of Spain: results from a national survey.
Ann Rheum Dis 2001; 60:1040-5.
6. White KP, Speechley M, Harth M, Ostbye T. The
London fibromyalgia epidemiology study: the prevalence
of fibromyalgia syndrome in London, Ontario. J Rheumatol
1999; 26:1577-85.
7 Wolfe F, Ross K, Anerson J, Russell IJ, Hebert L. The
prevalence and characteristics of fibromyalgia in the general
population. Arthritis Rheum 1995; 38:19-28.
8. Topbas M, Cakirbay H, Gulec H, Akgol E, Ak I, Can G. The
prevalence of fibromyalgia in women aged 20-64 in Turkey.
Scand J Rheumatol 2005; 34:140-4.
9. Jaime da Cunha Branco, Wessely S. Fibromyalgia from
complaints to evidence. Sótt 30. janúar 2007 af http://www.
entretiens-du-carla.com/publication.php?pub=fibro
10. Cavalcante AB, Sauer JF, Chalot SD, et al. The prevalence of
fibromyalgia: a literature review. Rev Bras Reumatol 2006; 46:
40-8.
11. Varni JW, Burwinkle TM, Limbers CA, Szer IS.The PedsQL as
a patient-reported outcome in children and adolescents with
fibromyalgia: an analysis of OMERACT domains. Health
Qual Life Outcomes 2007; 16; 5:43.
12. Siegel DM, Janeway D, Baum J. Fibromyalgia syndrome in
children and adolescents: clinical features at presentation and
status at follow-up. Pediatrics 1998; 101: 377-82.
13. Tayag-Kier CE, Keenan GF, Scalzi LV, et al. Sleep and periodic
limb movement in sleep in juvenile fibromyalgia. Pediatrics
2000; 106: E70.
14. Wolfe F, Smythe HA, Yunus MB, et al. The American College
of Rheumatology 1990 Criteria for the classification of
fibromyalgia. Report of the multicenter criteria committee.
Arthritis Rheum 1990; 33:160-72.
15. Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P,
Marina FF. Prevalence of fibromyalgia in children: a clinical
study of Mexican children. J Rheumatol 1998; 25: 2009-14.
16. Kashikar -Zuck S, Fraham TB, Hunenefeld MD, Powers
SW. A review of biobehavioral reserch in juvenile primary
fibromyalgia syndrome. Arthritis Care Res 2000; 13: 338-97.
17. Reid GJ, Lang BA, McGarth PJ. Primary juvenile fibromyalgia:
psychological adjustment, family functioning, coping, and
functional disability. Arthritis Rheum 1997; 40: 752-60.
18. Fibromyalgia: for a multidisciplinary support added to a
pharmaceutical treatment. Sótt 31.júlí 2007 af http://www.
entretiens-du-carla.com/print.php?pub=fibro3&pg=recom
mendations
19. Anthony KK, Schanberg LE. Juvenile primary fibromyalgia
syndrome. Curr Rheumatol Rep 2001; 3:165-71.
20. Bowyer S, Roettcher P. Pediatric rheumatology clinic
population in the United States: results of 3 year survey. J
Rheumatol 1996; 23:1968-74.
21. Buskila D, Press J, Gedalia A, et al. Assessment of nonarticular
tendemess and prevalence of fibromyalgia in children. J
Rheumatol 1993; 20:368-70.
22. Mikkelsson M. One year outcome of preadolescents with
fibromyalgia. J Rheumatol 1999; 26: 674-82.
23. White KP. Fibromyalgia: the answer is blowin' in the wind. J
Rheumatol 2004; 31: 636-9.
24. Buskila D, Neumann L. Genetics of fibromyalgia. Curr Pain
Headache Rep 2005; 9: 313-5. Review.
25. Buskila D, Neumann L, Hazanov I, Carmi R. Familial
aggregation in the fibromyalgia syndrome. Semin Arthritis
Rheum 1996; 26: 605-11.
26. Amold LM, Hudson JI, Hess EV, et al. Family study of
fibromyalgia. Arthritis Rheum 2004; 50: 944-52.
27. Pellegrino MJ, Waylonis GW, Sommer A. Familial occurrence
of primary fibromyalgia. Arch Phys Med Rehabil 1989; 70:
61-3.
28. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of
fibromyalgia syndrome. Pharmacogenomics 2007; 8: 67-74.
29. Buskila D, Neumann L. Fibromyalgia syndrome (FM) and
nonarticular tendemess in relatives of patients with FM. J
Rheumatol 1997; 24: 941-4.
30. Offenbaecher M, Bondy B, de Jonge S, et al. Possible
association of fibromyalgia with a polymorphism in the
serotonin transporter gene regulatory region. Arthritis
Rheum 1999; 42: 2482-8.
31. Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation
of an association between fibromyalgia and serotonin
transporter promoter region (5- HTTLPR) polymorphism,
and relationship to anxiety-related personality traits.
Arthritis Rheum 2002; 46: 845-7.
32. Buskila D, Cohen H, Neumann L, Ebstein RP. An association
between fibromyalgia and the dopamine D4 receptor exon
III repeat polymorphism and relationship to novelty seeking
personality traits. Mol Psychiatry 2004; 9: 730-1.
33. Gúrsoy S, Erdal E, Herken H, Madenci E, Ala_ehirli B,
Erdal N. Significance of catechol-O-methyltransferase gene
polymorphism in fibromyalgia syndrome. Rheumatol Int
2003; 23:104-7. Epub 2002 Oct 22.
34. Moldofsky H. Clinical and experimental studies on the
contribution of disordered sleep to pain and fatigue in
fibromyalgia / chronic fatigue syndrome and related
conditions. Sótt 6. nóvember 2006 af http://www.entretiens-
du-carla.com/publication.php?pub=fibro2&pg=clinical
35. Moldofsky H, Scarisbrick P, England R, Smythe H.
Musculoskeletal symptoms and non-REM sleep disturbance
in patients with fibrositis syndrome and healthy subjects.
Psychosom Med 1975; 37: 341-51.
36. Dauvilliers Y, Touchon J. Sleep in fibromyalgia: Review of
clinical and polysomnographic data. Neurophysiol Clin
2001; 31:17-33. Review.
37. Harding SM. Sleep in fibromyalgia patients: Subjective and
objective findings. Am J Med Sci 1998; 315: 367-76. Review.
38. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal
fluid biogenic amine metabolites in fibromyalgia/fibrositis
syndrome and rheumatoid arthritis. Arthritis Rheum 1992;
35: 550-6.
39. Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J. Serotonin
levels, pain threshold, and fibromyalgia symptoms in the
general population. J Rheumatol 1997; 24: 555-9.
40. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated
CSF levels of substance P and high incidence of Raynaud
phenomenon in patients with fibromyalgia: new features for
diagnosis. Pain 1988; 32: 21-6.
470 LÆKNAblaðið 2008/94